Referencias
  • Boulton AJ, Ironer RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004;351(1):48-55.

  • Reiber GE. The epidemiology of diabetic foot problems. Diabetic Med 1996;13 Suppl 1:S6-11.

  • Cinza AM, Quintana M, Lombardero J, et al. A batch process for production of human Epidermal Growth Factor in yeast. Product characterization. Biotecnología Aplicada 1991;8:166-174.

  • Prats P, Castañeda L, Falcón V, et al. Efecto del Factor de Crecimiento Epidérmico sobre la regeneración del nervio ciático transectado en ratas. Biotecnología Aplicada 1998, 15:237-241.

  • Berlanga J, Caballero ME, Ramirez D, et al. Epidermal growth factor protects against carbon tetrachloride-induced hepatic injury. Clinical Science (Lond) 1998,94:219-223.

  • Berlanga J., Lodos J., and López-Saura P. Attenuation of internal organs damages by exogenously administered epidermal growth factor (EGF) in burned rodents. BURNS 2002, 28: 435-442.

  • Caballero M.E., Berlanga J., Ramírez D., et al. Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut 2001, 48: 34-40.

  • Berlanga-Acosta J., Playford R.J., Mandir N., Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut 2001, 48: 803-807.

  • Berlanga J., Prats P., Remírez D., et al. Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. Am J Pathol 2002, 161: 373-379.

  • Sasaki M., FitzGerald A.J., Mandir N., Berlanga-Acosta J., Goodlad R.A. Keratinocyte growth factor and epidermal growth factor can reverse the intestinal atrophy associated with elemental diets in mice. Exp Physiol 2003, 88: 261-267.

  • Anmstrong D.G., Lavery L.A., Harkless L.B. Validation of a Diabetic Wound Classification System: The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998, 21 (5): 855-859.

  • Berlanga J., Savigne W., Valdez C., et al. Epidermal Growth Factor Intra-lesional can prevent amputation in diabetic patients with advanced foot wounds. Int Wound J 2006, 3 (3): 232-9.

  • Fernández-Montequín J.I., Infante-Cristiá E., Valenzuela-Silvia C., et al. Intra-lesional injections of Citoprot-P® (recombinant human Epidermal Growth Factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007, 4: 333-43.

  • Fernández-Montequín J.I., Betancourt B.Y., Leyva-González G., et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot- P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J 2009, 6 (1): 67-72.

  • Berlanga-Acosta J., Gavilondo-Cowley J., López-Saura P., et al. Epidermal Growth Factor (EGF) in clinical practice-A review of its biological actions, clinical indications and safety implications. Int Wound J 2009 (in press).